The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 09, 2021

Filed:

Jul. 16, 2019
Applicants:

Regeneran Pharmaceuticals, Inc., Tarrytown, NY (US);

Sanofi Biotechnology, Paris, FR;

Inventors:

Allen Radin, New York, NY (US);

Neil Graham, Croton-On-Hudson, NY (US);

Bolanle Akinlade, White Plains, NY (US);

Gianluca Pirozzi, Bridgewater, NJ (US);

Xing Sun, Bridgewater, NJ (US);

Thomas Hultsch, Bridgewater, NJ (US);

Brad S. Shumel, Chappaqua, NY (US);

Ashish Bansal, White Plains, NY (US);

Assignees:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Sanofi Biotechnology, Paris, FR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/24 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 38/02 (2006.01); A61P 17/00 (2006.01); C07K 16/28 (2006.01); A61K 9/00 (2006.01); C07K 7/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/02 (2013.01); A61K 9/0019 (2013.01); A61K 45/06 (2013.01); A61P 17/00 (2018.01); C07K 7/06 (2013.01); C07K 16/247 (2013.01); C07K 16/2866 (2013.01); A61K 39/395 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01);
Abstract

The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present invention are used to treat severe AD in a patient whose disease is not controlled with systemic therapy (e.g., cyclosporine A) or when such therapy is inadvisable.


Find Patent Forward Citations

Loading…